Abstract CT183: CD5+ B-cell count is a favorable prognostic factor associated with progression-free survival in glioblastoma patients receiving chemoradiation and pembrolizumab by Claunch, Cheryl J., Diaz, Claire, Roth-Carter, Riley A., Popp, Lauren, Fu, Rochelle, Huddleston, Amy E., Moussalli, Dana L., Peterson, Julie, Uluc, Kutluay, Szidonya, Laszlo, Fan, Guang, Pucci, Ferdinando, Barajas, Ramon F., Muldoon, Leslie L., Neuwelt, Edward A., Ambady, Prakash

Get full text